Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lung Neoplasms 22Breast Neoplasms 18Hematologic Neoplasms 17Colorectal Neoplasms 13Prostatic Neoplasms 11Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Pancreatic Neoplasms 9Hematopoietic and Lymphatic System Neoplasm 8Anatomic Stage I Breast Cancer AJCC v8 8Urinary Bladder Neoplasms 6Ovarian Neoplasms 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Multiple Myeloma 5Melanoma 5Head and Neck Carcinoma 5Breast Carcinoma In Situ 5Triple Negative Breast Neoplasms 4Stomach Neoplasms 4Hematopoietic and Lymphoid System Neoplasm 4Mouth Neoplasms 3Lymphoma 3Leukemia, Myeloid, Acute 3Head and Neck Neoplasms 3Esophageal Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Carcinoma 3

Interventions

ixabepilone 1Standard of Care 1Practice Guidelines as Topic 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Bilateral Breast Carcinoma × Practice Guidelines as Topic × Clear all
NCT00877500 2026-05-22

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
116 enrolled
Breast

Bilateral Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡